Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 2011- -002792

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7383   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    435 result(s) found for: 2011- -002792. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-000524-25 Sponsor Protocol Number: CAIN457A2318 Start Date*: 2017-02-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018190 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-000518-39 Sponsor Protocol Number: CAIN457A2325 Start Date*: 2018-12-06
    Sponsor Name:Novartis Pharma AG
    Full Title: Multicenter, rAndomized, double-blind, placebo-conTrolled, 52-week stUdy to demonstRatE the efficacy, safety and tolerability of subcutaneous secukinumab injections with 2 mL auto-injectors (300 mg...
    Medical condition: Moderate to severe plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2014-005339-15 Sponsor Protocol Number: CAIN457A3302 Start Date*: 2015-05-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 ...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) IE (Completed) NL (Completed) CZ (Completed) SK (Completed) AT (Completed) BE (Completed) HU (Completed) SE (Completed) DE (Completed) BG (Completed) DK (Completed) FI (Completed) LV (Completed) LT (Completed) FR (Completed) GR (Completed) GB (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002898-37 Sponsor Protocol Number: CAIN457A2326 Start Date*: 2016-05-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) IS (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004620-60 Sponsor Protocol Number: CAIN457A2324 Start Date*: 2018-06-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 ...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004515-39 Sponsor Protocol Number: CAIN457A2311 Start Date*: 2018-10-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, open-label, multicenter trial to assess the efficacy of subcutaneous secukinumab after twelve weeks of treatment, and to assess the long-term safety, tolerability and efficacy in subj...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing) DE (Completed) CZ (Completed) EE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005258-20 Sponsor Protocol Number: CAIN457ADE06 Start Date*: 2015-03-13
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 24-week, randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm® in adults with moderate to severe plaque p...
    Medical condition: chronic moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001250-28 Sponsor Protocol Number: RBHP 2011 BONNIN Start Date*: 2011-06-10
    Sponsor Name:CHU de Clermont-Ferrand
    Full Title:
    Medical condition:
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001975-37 Sponsor Protocol Number: KA1 Start Date*: 2006-03-22
    Sponsor Name:North West London NHS Trust
    Full Title: A pilot study to examine the efficacy of vaginally administered oestradiol in the treatment of faecal incontinence in post menopausal women
    Medical condition: Faecal Incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013957-13 Sponsor Protocol Number: 020173 Start Date*: 2009-09-21
    Sponsor Name:Helsinki University Central Hospital
    Full Title: The effect of levosimendan on blood coagulation after cardiac surgery.
    Medical condition: Sepelvaltimotauti I20.0 Sydämen vajaatoiminta I50.0
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005170-38 Sponsor Protocol Number: CAIN457A2323 Start Date*: 2016-09-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LV (Completed) BE (Completed) ES (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2014-005663-32 Sponsor Protocol Number: CAIN457A2310 Start Date*: 2015-08-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single blinded arm) after t...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Completed) DE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005413-40 Sponsor Protocol Number: CAIN457A2313 Start Date*: 2013-04-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and longterm effi...
    Medical condition: Moderate to severe nail psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10028703 Nail psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020924-22 Sponsor Protocol Number: RG_09-072 Start Date*: 2011-12-02
    Sponsor Name:University of Birmingham
    Full Title: United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011
    Medical condition: Acute lymphoblastic leukaemia and lymphoblastic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    18.1 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003701-42 Sponsor Protocol Number: CAIN457A3401 Start Date*: 2016-02-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque ...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed) BE (Completed) LV (Completed) PT (Completed) SK (Completed) LT (Completed) PL (Completed) GR (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000634-34 Sponsor Protocol Number: 13704501 Start Date*: 2014-05-19
    Sponsor Name:CHU Toulouse
    Full Title: IFM 2014-02 study: A randomized phase III study of Bortezomib-Melphalan 200 conditioning regimen versus Melphalan 200 for frontline transplant eligible patients with multiple myeloma
    Medical condition: Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001856-12 Sponsor Protocol Number: NT-12331-5 Start Date*: 2011-08-11
    Sponsor Name:The Motol University Hospital
    Full Title: Early assessment of effectivness of neoadjuvant chemotherapy for carcinoma of the esophagus and esophago-gastric junction using FDG-PET/CT.
    Medical condition: adenocarcinoma of the esophagus and esophago-gastric junction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001892-38 Sponsor Protocol Number: CTPN01 Start Date*: 2011-07-22
    Sponsor Name:Panin S.r.l.
    Full Title: A randomised, controlled, assessor-blind, clinical trial to compare Liceko ® with NIX/Lyclear 1% permethrin crème rinse in the treatment of head lice.
    Medical condition: Head louse infestation (pediculosis capitis)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10034214 Pediculus capitis (head louse) LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001974-32 Sponsor Protocol Number: CAIN457ADE04 Start Date*: 2015-04-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300 mg s.c.) in comparison to continued standard treatme...
    Medical condition: chronic moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002027-26 Sponsor Protocol Number: 2405 Start Date*: 2016-04-13
    Sponsor Name:University of Bristol
    Full Title: TARGETING DOPAMINE TO TREAT IMPAIRED MEMORY CONSOLIDATION IN NEURODEGENERATIVE DISEASE: A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
    Medical condition: Mild Cognitive Impairment Mild Alzheimer's disease
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Oct 05 03:57:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA